<DOC>
	<DOCNO>NCT00951899</DOCNO>
	<brief_summary>The goal study determine metabolic mechanism certain type medication 's ability lower blood sugar meal Type 2 Diabetics , order develop well understanding 's potential role treatment obesity .</brief_summary>
	<brief_title>The Effect Welchol Glucose Metabolism Type 2 Diabetics</brief_title>
	<detailed_description>Welchol ( colesevelam hydrochloride ) bile acid sequestrant ( BAS ) recently approve FDA glucose lower patient type 2 diabetes mellitus . Four randomized , control clinical study subject type 2 diabetes demonstrate significant treatment difference HbA1c ( -0.5 % ) . Study duration range 12-26 week therapy . In diabetes clinical study , therapeutic response colesevelam hydrochloride , reflect reduction A1c initially note follow 4-6 week treatment reach maximal near-maximal effect 12-18 week treatment . Reductions fast plasma glucose postprandial concentration demonstrate . Simple measure insulin secretion action suggest due improve insulin action rather improved insulin secretion . The mechanism bile acid interact key pathway regulate glucose concentration largely unknown . The investigator propose randomize , double-blind , placebo control trial parallel-group design subject randomize receive colesevelam match placebo 12 week treatment period . A labeled mixed meal treatment use measure intestinal transit , postprandial fast glucose flux , insulin secretion action well enteroendocrine secretion .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Age 3570 year old . Body Mass Index great 19kg/m^2 less 40kg/m^2 total weight le 130 kilogram . Negative pregnancy test woman childbearing potential . Absence gastrointestinal symptom . Signed informed consent . Treatment diet and/or metformin . Subjects must stable therapeutic dos metformin and/or lipidlowering agent 3 month . Structural metabolic diseases/conditions affect gastrointestinal system , functional gastrointestinal disorder . A screening Bowel Disease Questionnaire use exclude subject irritable bowel syndrome . Patients history dysphagia intestinal motility disorder exclude . Prior history pancreatitis . Prior history hypertriglyceridemia ( 500mg/dL great ) . Currently use bileacid bind resin colesevelam , colestipol , colestimide cholestyramine . To ensure homogeneity treatment group exclude subject insulintreated type 2 diabetes mellitus , subject receive inhibitor dipeptidyl peptidase 4 ( DPP4 inhibitor ) `` gliptins '' ( class oral hypoglycemics ) , Byetta sulfonylurea agent past three month . HbA1c great 9.0 % . Patients stable medication period exceed 3 month . Use drug agent within past 2 week plan use subsequent 4 week study period : Alter GI transit include laxative , magnesium aluminumcontaining antacid , prokinetics , erythromycin , narcotic , anticholinergic , tricyclic antidepressant , Selective Serotonin Reuptake Inhibitors ( SSRIs ) new antidepressant . Opiatebased analgesic drug ( Note : intermittent chronic use aspirin nonsteroidal antiinflammatory drug ( NSAID ) allow ) . Antihistamines Anticholinergic agent Female subject pregnant breastfeeding . Females must either surgically sterilize , postmenopausal ( &gt; 12 month since last menses ) , , childbearing potential , use reliable method contraception determine physician . Clinical evidence ( include physical exam Electrocardiogram ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study . Any candidate participant disorder mention referred general physician .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Incretins</keyword>
	<keyword>colesevelam</keyword>
	<keyword>hepatobiliary circulation</keyword>
</DOC>